Effects of Quetiapine Combined with Vortioxetine on Sleep Electroencephalogram and Peripheral Blood Brain-Derived Neurotrophic Factor in Patients with Treatment-Resistant Depression
Objective:To investigate the clinical efficacy of quetiapine combined with vortioxetine in the treatment of treatment-resistant depression and its effects on sleep electroencephalogram and brain-derived neurotrophic factor(BDNF)level of patients.Methods:A total of 94 patients with treatment-resistant depression treated in a hospital from February 2021 to August 2023 were selected and assigned to the control group(with 1 patient excluded due to unauthorized drug discontinuation)and the observation group(with 1 patient excluded due to unauthorized addition of other antidepressants)using a random number table method,resulting in 46 patients enrolled in each group.Patients in the control group was treated with vortioxetine hydrobromide tablets,while patients in the observation group was treated with quetiapine fumarate tablets on the basis of control group.The clinical efficacy,Wisconsin card sorting test(WCST)score,peripheral blood BDNF-related factors[BDNF,BDNF precursor(proBDNF),mature BDNF(mBDNF),tyrosine kinase receptor B(TrkB)],sleep electroencephalogram parameters[sleep latency,awakening frequency,awakening time,total sleep time,sleep efficiency]and adverse reactions were compared between the two groups.Results:After treatment,the total effective rate in the observation group(89.13%)was higher than that in the control group(71.74%,P<0.05).The number of perseverative errors,random errors,proBDNF level,sleep latency,awakening frequency and awakening time were decreased in both groups,with the observation group showing lower values than those in the control group(P<0.05).The number of correct responses,BDNF level,mBDNF level,TrkB level,total sleep time and sleep efficiency were increased in both groups,with the observation group showing higher values than those in the control group(P<0.05).During the treatment period,no statistically significant difference in the total incidence of adverse reactions was observed between the two groups(P>0.05).Conclusion:Quetiapine combined with vortioxetine shows better clinical efficacy in the treatment of patients with treatment-resistant depression,significantly improving sleep electroencephalogram and regulating BDNF-related factors,with no increased risk of adverse events.
万方数据
维普
